Skip to content
Get Claritide

The Four-Minute Peptide

Kisspeptin-10

Also known as KP-10 · Metastin(45–54)

At a glance

What it is
The famous HSDD trials used kisspeptin-54. This is kisspeptin-10.
Evidence
Small human studiesHow the tiers workThe kisspeptin evidence base is real, intravenous, and mostly about a different molecule. Why this tier
Half-life
4 minutes (plasma, intravenous).
Routes
Intravenous, Subcutaneous
Category
Sexual health
FDA
FDA Category 2
As of 3 August 2026. What that means
WADA
We do not state a status
Amino acids
10

Not schedulable in Claritide. Our sources publish no dosing figure for Kisspeptin-10, so there is nothing to build a schedule from.

Evidence

Why this tier

The kisspeptin evidence base is real, intravenous, and mostly about a different molecule. The widely cited desire-and-arousal trials from Imperial College used kisspeptin-54 at 1 nmol/kg/h infused over 75 minutes: in women with HSDD (JAMA Network Open, 26 October 2022, 32 premenopausal women completing both visits) modified fMRI activation to erotic stimuli, LH +2.14 IU/L, no significant change in downstream sex steroids, and a modest exploratory increase in self-reported sexiness. The men’s study from the same group reported penile tumescence 56% above placebo; the peptide form was not independently confirmed and we assume KP-54 by group convention while marking it unverified. Kisspeptin-10 has its own human pharmacology, all intravenous, and there is no human trial evidence for subcutaneous kisspeptin-10 at all.

Overview

What it is

Kisspeptin-10 is a ten-amino-acid fragment that stimulates gonadotropin-releasing hormone neurons and, downstream, luteinising hormone and testosterone. Every human dataset for it is intravenous, and its plasma half-life is four minutes. The widely cited desire-and-arousal trials used a different molecule: kisspeptin-54, which has a half-life of 27.6 minutes. The market sells KP-10 while citing them.

Mechanism

How it works

Kisspeptin sits at the top of the reproductive hormone axis. It acts on kisspeptin receptors on gonadotropin-releasing hormone neurons in the hypothalamus, which raises GnRH pulse output; GnRH then drives luteinising hormone and follicle-stimulating hormone from the pituitary, and LH drives testosterone from the testes. That cascade is well documented in humans by intravenous infusion. Two details matter more than the cascade itself. First, the dose-response is non-monotonic: in men, an intravenous bolus of 1 mcg/kg produced maximal LH stimulation and 3 mcg/kg produced a smaller response than 1 mcg/kg. More is not more. Second, kisspeptin-10 has a plasma half-life of four minutes, which constrains what any single subcutaneous injection can plausibly do.

Dosing

Commonly researched ranges

These are figures reported in published literature and practitioner protocols: a commonly researched range, not a recommendation. Claritide does not tell you what to take.
  • Maximal LH stimulation (IV bolus, men)1 mcg/kg

    × body weight in kg

    Single intravenous bolus

    JCEM 2011 (PMID 21632807): LH rose from 4.1 ± 0.4 to 12.4 ± 1.7 IU/L at 30 minutes. A 3 mcg/kg bolus produced a smaller response than 1 mcg/kg: the curve turns over.

  • Continuous infusion (men)1.5–4 mcg/kg

    × body weight in kg

    Per hour, intravenously, for 22.5 hours at the higher rate

    At 4 mcg/kg/h for 22.5 hours LH went from 5.4 to 20.8 IU/L and testosterone from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/L. At 1.5 mcg/kg/h LH went from 5.2 to 14.1 IU/L with pulse frequency rising from 0.7 to 1.0 per hour.

Cycle guidance
No cycling schedule exists. Every published human protocol is an acute intravenous bolus or an infusion lasting hours, run in a research setting.
Goals
Libido
Legal standing

Where this sits with the FDA

Dated, sourced, and separate from whether it works. Removal from a warning list is not permission to compound.
FDA Category 2as of 3 August 2026 · US

503A Category 2 · bulk substances that may present significant safety risks

Kisspeptin-10 is one of the few compounds in this library with a live FDA "significant safety risk" designation, cited on immunogenicity grounds and for absent or limited safety information. It was not part of the April 2026 removals.

Last change · 29 September 2023 · Added to the 503A Category 2 list on 29 September 2023.

Primary source

How it got here

  1. 29 September 2023

    FDA placed kisspeptin-10 in 503A Category 2, citing immunogenicity and no or limited safety information.

Sport

WADA status

The 2026 Prohibited List entered force on 1 January 2026.
We do not state a status

Not named on the 2026 Prohibited List. We could not determine whether the S0 catch-all applies and do not state a status. Note separately that anything raising luteinising hormone is in territory anti-doping authorities care about.

We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.

Reconstitution

Mixing recipes our sources document

Concentration (mg/mL) = vial mg ÷ diluent mL. On a U-100 barrel, 1 unit = 0.01 mL.

Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator

Expectations

Week by week

What our material describes people reporting. Individual responses vary widely.

Not established in available literature.

Tolerability

Side effects

Grouped by how often our sources report them. Percentages appear only where a published trial figure exists.

Rare

  • No significant adverse effects reported in the trialsThe 2015 Human Reproduction review states that kisspeptin has been administered to human subjects without any significant acute or chronic adverse effects, and the HSDD infusion studies reported none. Those are short intravenous exposures in supervised settings. They do not establish the safety of repeated subcutaneous self-administration.
Safety

Contraindications and interactions

Do not use if

Not established in available literature.

Interactions

Not established in available literature.

Absence from this list does NOT mean safety. It means lack of research.

Handling

Storage and cost

Storage
Our sources publish no vial and diluent pairing or beyond-use window for kisspeptin-10. Every human protocol we can cite was prepared for intravenous administration in a research setting.
Cost
Not established in available literature
Deep dive

Kisspeptin-10 in full

The correction that justifies this record

The famous kisspeptin trials, the ones every vendor page links to showing changes in brain response to erotic stimuli and improvements in self-reported desire, used kisspeptin-54.

The product being sold is kisspeptin-10.

They are different molecules with different pharmacokinetics. Kisspeptin-10 has a plasma half-life of 4 minutes. Kisspeptin-54 has a half-life of 27.6 minutes, nearly seven times longer. In the trials, KP-54 was not given as a single injection either; it was infused continuously for 75 minutes.

What the desire trials actually found

Women with HSDD, JAMA Network Open, 26 October 2022: kisspeptin-54 at 1 nmol/kg/h infused intravenously over 75 minutes. 40 randomised, 32 premenopausal women completing both visits, mean age 29.2. The findings: modified fMRI activation to erotic stimuli, LH up 2.14 IU/L, FSH up 0.28 IU/L, no significant change in downstream sex steroids, and a modest exploratory increase in self-reported "sexiness". Kisspeptin was well tolerated with no reported adverse effects.

Read that carefully. The primary outcomes are brain imaging and pituitary hormones. The subjective effect is exploratory and modest. Testosterone and oestrogen did not move.

Men with HSDD, same Imperial College group: 32 men, mean age 37.9, double-blind two-way crossover, 75-minute infusion, penile tumescence 56% above placebo, no adverse events. The peptide form was not independently confirmed in our checking. We assume KP-54 by the group's convention and mark it unverified.

Kisspeptin-10's own pharmacology

It exists, and it is worth knowing, because it contains a lesson.

JCEM 2011 (PMID 21632807), healthy men: an intravenous bolus of 1 mcg/kg produced maximal LH stimulation, taking LH from 4.1 ± 0.4 to 12.4 ± 1.7 IU/L at 30 minutes. A 3 mcg/kg bolus produced a smaller response than 1 mcg/kg. The dose-response curve turns over. Tripling the dose made it work less well.

Infusion at 4 mcg/kg/h for 22.5 hours: LH from 5.4 to 20.8 IU/L, testosterone from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/L. At 1.5 mcg/kg/h: LH from 5.2 to 14.1 IU/L, with pulse frequency rising from 0.7 to 1.0 per hour.

So kisspeptin-10 genuinely drives the reproductive axis in humans, by continuous intravenous infusion, in a research setting, over hours.

What that means for how it is sold

There is no human trial evidence for subcutaneous kisspeptin-10. That is the route the community uses.

And a four-minute plasma half-life makes the standard framing, 100 mcg subcutaneously before a workout for a sustained effect, pharmacologically implausible on its face. Whatever a subcutaneous injection of a four-minute peptide does, it is not what a 22-hour infusion did.

Regulatory

Kisspeptin-10 is still in Category 2 under 503A, added 29 September 2023, on immunogenicity grounds and for absent or limited safety information. It is one of the few compounds in this library carrying a live FDA "significant safety risk" designation, and it was not part of the April 2026 removals.

References

Sources

  1. 1
    JCEM 2011 · kisspeptin-10 pharmacology in men, dose-response and infusion studies
    PMID 21632807Source
  2. 2
    JAMA Network Open, 26 October 2022 · kisspeptin-54 in women with HSDD
    Source
  3. 3
    JAMA Network Open · kisspeptin administration in men with HSDD
    Source
  4. 4
    Human Reproduction, 2015 · kisspeptin-10 plasma half-life 4 minutes, kisspeptin-54 27.6 minutes
    Source

Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.